HER2/HER3 pathway in biliary tract malignancies; systematic review and meta-analysis: a potential therapeutic target?
Open accessThe DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.
Abstract
Human epidermal growth factor receptor 2 (HER2) overexpression and amplification have been reported as predictive markers for HER2-targeted therapy in breast and gastric cancer, whereas human epidermal growth factor receptor 3 (HER3) is emerging as a potential resistance factor. The aim of this study was to perform a systematic review and meta-analysis of the HER2 and HER3 overexpression and amplification in biliary tract cancers (BTCs). An electronic search of MEDLINE, American Society of Clinical Oncology (ASCO), European Society of Medical Oncology Congress (ESMO), and American Association for Cancer Research (AACR) was performed to identify studies reporting HER2 and/or HER3 membrane protein expression by immunohistochemistry (IHC) and/or gene amplification by in situ hybridization (ISH) in BTCs. Studies were classified as "high quality" (HQ) if IHC overexpression was defined as presence of moderate/strong staining or "low quality" (LQ) where "any" expression was considered positive. Of 440 studies screened, 40 met the inclusion criteria. Globally, HER2 expression rate was 26.5 % (95 % CI 18.9-34.1 %). When HQ studies were analyzed (n = 27 studies), extrahepatic BTCs showed a higher HER2 overexpression rate compared to intrahepatic cholangiocarcinoma: 19.9 % (95 % CI 12.8-27.1 %) vs. 4.8 % (95 % CI 0-14.5 %), respectively, p value 0.0049. HER2 amplification rate was higher in patients selected by HER2 overexpression compared to "unselected" patients: 57.6 % (95 % CI 16.2-99 %) vs. 17.9 % (95 % CI 0.1-35.4 %), respectively, p value 0.0072. HER3 overexpression (4/4 HQ studies) and amplification rates were 27.9 % (95 % CI 9.7-46.1 %) and 26.5 % (one study), respectively. Up to 20 % of extrahepatic BTCs appear to be HER2 overexpressed; of these, close to 60 % appear to be HER2 amplified, while HER3 is overexpressed or amplified in about 25 % of patients. Clinical relevance for targeted therapy should be tested in prospective clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & the PRISMA Group* (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-151-4-200908180-00135 · Cited by 37,554
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500 · cited 1×
“The human epidermal growth factor receptor 2 (HER2), which belongs to the ErbB/(HER) family of receptor tyrosine kinases (TK), is a well-described predictive biomarker for anti-HER2 therapy in breast and gastric cancer [5, 6].”
Bang, Y.-J., Van Cutsem, E., Feyereislova, A., Chung, H. C., Shen, L., Sawaki, A., Lordick, F., Ohtsu, A., Omuro, Y., Satoh, T., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61121-x · Cited by 7,302 · cited 5×
“The primary objective of this systematic review and metaanalysis was to assess the prevalence of HER2 overexpression Table 1 Standardized guidelines for HER2 analysis, adjusted from 2013 ASCO/CAP guidelines for the HercepTestTM scoring system in breast cancer [26] and standardized guidelines (for both surgical and bio…”
InfluentialMET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496 · cited 1×
“Finally, HER3 has the ability to dimerize with both HER family members and nonHER family members such as mesenchymal epithelial transition (MET) receptor [24, 25], contributing to anti-HER2 therapy resistance.”
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
Valle, J., Wasan, H., Palmer, D. H., Cunningham, D., Anthoney, A., Maraveyas, A., Madhusudan, S., Iveson, T., Hughes, S., Pereira, S. P., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0908721 · Cited by 4,406 · cited 1×
“The prognosis for patients with advanced biliary tract cancers (BTCs) is very poor with a median overall survival of less than 12 months following treatment with systemic chemotherapy [1].”
Self-citationWolff, A. C., Hammond, M. E. H., Hicks, D. G., Dowsett, M., McShane, L. M., Allison, K. H., Allred, D. C., Bartlett, J. M. S., Bilous, M., Fitzgibbons, P., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.50.9984 · Cited by 4,030 · cited 11×
“When all studies were included (regardless of applying ISH for Bselected^ or Bunselected^ population), mean HER2 amplification rate was statistically significantly higher in patients with EH-BTCs compared to IHCCs (Table 4).”
InfluentialERBB receptors and cancer: the complexity of targeted inhibitors
Hynes, N. E., & Lane, H. A. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1609 · Cited by 3,313
(2012) · Hepatogastroenterology · doi:10.5754/hge12469 · Cited by 3,178
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Aebi, S., Davidson, T., Gruber, G., & Castiglione, M. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq159 · Cited by 2,842
Trastuzumab — Mechanism of Action and Use in Clinical Practice
Hudis, C. A. (2007) · New England Journal of Medicine · doi:10.1056/nejmra043186 · Cited by 2,585 · cited 1×
“Dimerization induces the activation of the intrinsic tyrosine kinase domain, by phosphorylation of specific tyrosine residues, leading to the activation of different downstream signaling cascades, including the mitogenactivated protein kinase (MAPK) proliferation pathway and phosphatidylinositol 3-kinase (PI3K)/protei…”
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Senkus, E., Kyriakides, S., Ohno, S., Penault-Llorca, F., Poortmans, P., Rutgers, E., Zackrisson, S., & Cardoso, F. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv298 · Cited by 1,597 · cited 1×
“AntiHER2 therapy options might include the antibodies trastuzumab, pertuzumab, or trastuzumab emtansine (T-DM1) or the small-molecule, orally active, TKI, lapatinib [6, 90, 91].”
Graus-Porta, D. (1997) · The EMBO Journal · doi:10.1093/emboj/16.7.1647 · Cited by 1,590 · cited 4×
“The HER family consists of four receptors [HER1 (EGFR), HER2, HER3, and HER4] with similar structure, consisting of four main parts: an extracellular ErbB ligand-binding domain, a single transmembrane lipophilic segment, an intracellular tyrosine kinase domain, and an intracellular C-terminal tail [15].”
InfluentialAssessment of a HER2 scoring system for gastric cancer: results from a validation study
Hofmann, M., Stoss, O., Shi, D., Büttner, R., Van De Vijver, M., Kim, W., Ochiai, A., Rüschoff, J., & Henkel, T. (2008) · Histopathology · doi:10.1111/j.1365-2559.2008.03028.x · Cited by 1,187
Novel anticancer targets: revisiting ERBB2 and discovering ERBB3
Baselga, J., & Swain, S. M. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2656 · Cited by 1,142 · cited 2×
“In contrast to HER2, HER3 can bind multiple ligands (neuregulins) [20] but it lacks a functioning kinase domain [21] and is, therefore, unable to homodimerize and to induce downstream signaling pathway activation on its own.”
Tzahar, E., Waterman, H., Chen, X., Levkowitz, G., Karunagaran, D., Lavi, S., Ratzkin, B. J., & Yarden, Y. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.10.5276 · Cited by 1,036 · cited 1×
“Although all four HER family receptors are capable of dimerizing with each other, HER2 is the preferred dimerization partner [19] and the HER2–HER3 dimer seems to be the most potent HER family dimer [22, 23].”
Science Translational Medicine
(2013) · Science Translational Medicine · doi:10.1126/scitranslmed · Cited by 859
Hecht, J. R., Bang, Y.-J., Qin, S. K., Chung, H. C., Xu, J. M., Park, J. O., Jeziorski, K., Shparyk, Y., Hoff, P. M., Sobrero, A., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.6598 · Cited by 624 · cited 1×
“Given the lack of benefit reported for lapatinib in previous phase II trials in BTCs [93, 94] as well as in phase III trials in HER2-positive advanced gastric cancer [95, 96], alternative anti-HER2 therapies such as monoclonal antibodies trastuzumab and pertuzumab seem to be more promising.”
Satoh, T., Xu, R.-H., Chung, H. C., Sun, G.-P., Doi, T., Xu, J.-M., Tsuji, A., Omuro, Y., Li, J., Wang, J.-W., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.6136 · Cited by 624 · cited 1×
“Given the lack of benefit reported for lapatinib in previous phase II trials in BTCs [93, 94] as well as in phase III trials in HER2-positive advanced gastric cancer [95, 96], alternative anti-HER2 therapies such as monoclonal antibodies trastuzumab and pertuzumab seem to be more promising.”
Garrett, T. P. J., McKern, N. M., Lou, M., Elleman, T. C., Adams, T. E., Lovrecz, G. O., Kofler, M., Jorissen, R. N., Nice, E. C., Burgess, A. W., et al. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00048-0 · Cited by 613 · cited 2×
“The extracellular ligand-binding region contains four domains (I–IV): domains I and III recognize and bind their corresponding ligands and domain II mediates receptor dimerization, whereas domain IV, interacting with domain II, leads to a negative feedback on the dimerization process [16].”
ErbB receptors: from oncogenes to targeted cancer therapies
Zhang, H., Berezov, A., Wang, Q., Zhang, G., Drebin, J., Murali, R., & Greene, M. I. (2007) · Journal of Clinical Investigation · doi:10.1172/jci32278 · Cited by 574 · cited 1×
“The HER family consists of four receptors [HER1 (EGFR), HER2, HER3, and HER4] with similar structure, consisting of four main parts: an extracellular ErbB ligand-binding domain, a single transmembrane lipophilic segment, an intracellular tyrosine kinase domain, and an intracellular C-terminal tail [15].”
Andersen, J. B., Spee, B., Blechacz, B. R., Avital, I., Komuta, M., Barbour, A., Conner, E. A., Gillen, M. C., Roskams, T., Roberts, L. R., et al. (2012) · Gastroenterology · doi:10.1053/j.gastro.2011.12.005 · Cited by 552 · cited 1×
“Eighteen studies were excluded after the full-text review as per our inclusion/exclusion criteria: 11 studies did not report an optimal distinction between cytoplasmic and membrane HER2/HER3 staining [29–39]; one study employed a method other than IHC and/or ISH for evaluating HER2/HER3 expression with no IHC/ISH data…”
MethodESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)
Cardoso, F., Costa, A., Norton, L., Senkus, E., Aapro, M., André, F., Barrios, C. H., Bergh, J., Biganzoli, L., Blackwell, K. L., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu385 · Cited by 540 · cited 1×
“AntiHER2 therapy options might include the antibodies trastuzumab, pertuzumab, or trastuzumab emtansine (T-DM1) or the small-molecule, orally active, TKI, lapatinib [6, 90, 91].”
Press, M. F., Hung, G., Godolphin, W. J., & Slamon, D. (1994) · PubMed · Cited by 478
Lee, J., Park, S. H., Chang, H.-M., Kim, J. S., Choi, H. J., Lee, M. A., Chang, J. S., Jeung, H. C., Kang, J. H., Lee, H. W., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70301-1 · Cited by 478
Gastric cancer—molecular and clinical dimensions
Wadhwa, R., Song, S., Lee, J.-S., Yao, Y., Wei, Q., & Ajani, J. A. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.170 · Cited by 423 · cited 8×
“When all studies were included (regardless of applying ISH for Bselected^ or Bunselected^ population), mean HER2 amplification rate was statistically significantly higher in patients with EH-BTCs compared to IHCCs (Table 4).”
InfluentialMalka, D., Cervera, P., Foulon, S., Trarbach, T., de la Fouchardière, C., Boucher, E., Fartoux, L., Faivre, S., Blanc, J.-F., Viret, F., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70212-8 · Cited by 408
Yoshikawa, D., Ojima, H., Iwasaki, M., Hiraoka, N., Kosuge, T., Kasai, S., Hirohashi, S., & Shibata, T. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604129 · Cited by 404
Valle, J. W., Furuse, J., Jitlal, M., Beare, S., Mizuno, N., Wasan, H., Bridgewater, J., & Okusaka, T. (2014) · Annals of Oncology · doi:10.1093/annonc/mdt540 · Cited by 391 · cited 1×
“Unfortunately, unlike other solid tumors, targetable biomarkers are lacking in BTCs and the cisplatin and gemcitabine combination remains gold standard first-line treatment worldwide in patients with advanced disease [2], with no proven benefit from targeted therapies as yet * Juan W.”
Self-citationFibroblast growth factor receptor 2 translocations in intrahepatic cholangiocarcinoma
Graham, R. P., Barr Fritcher, E. G., Pestova, E., Schulz, J., Sitailo, L. A., Vasmatzis, G., Murphy, S. J., McWilliams, R. R., Hart, S. N., Halling, K. C., et al. (2014) · Human Pathology · doi:10.1016/j.humpath.2014.03.014 · Cited by 313 · cited 2×
“Interestingly, the mean HER2 amplification rate was higher in the five studies [59, 68, 72, 73, 78] in which ISH test was performed in Bselected^ population when compared to the 12 studies in which ISH test was applied to Bunselected population^ only [17.”
A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer
Ramanathan, R. K., Belani, C. P., Singh, D. A., Tanaka, M., Lenz, H.-J., Yen, Y., Kindler, H. L., Iqbal, S., Longmate, J., Mack, P. C., et al. (2009) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-009-0927-7 · Cited by 284 · cited 1×
“Given the lack of benefit reported for lapatinib in previous phase II trials in BTCs [93, 94] as well as in phase III trials in HER2-positive advanced gastric cancer [95, 96], alternative anti-HER2 therapies such as monoclonal antibodies trastuzumab and pertuzumab seem to be more promising.”
Valle, J. W., Wasan, H., Lopes, A., Backen, A. C., Palmer, D. H., Morris, K., Duggan, M., Cunningham, D., Anthoney, D. A., Corrie, P., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00139-4 · Cited by 273
Self-citationNakazawa, K., Dobashi, Y., Suzuki, S., Fujii, H., Takeda, Y., & Ooi, A. (2005) · The Journal of Pathology · doi:10.1002/path.1779 · Cited by 234 · cited 3×
“reported data from 221 patients, 71 of whom had FISH testing performed: meaningful differences in HER2 amplification rate were shown between Bunselected^ [15/71 (21 %)] and Bselected^ [15/19 (79 %)] populations [59] (Table 2).”
HER2/neu-directed therapy for biliary tract cancer
Javle, M., Churi, C., Kang, H. C., Shroff, R., Janku, F., Surapaneni, R., Zuo, M., Barrera, C., Alshamsi, H., Krishnan, S., et al. (2015) · Journal of Hematology & Oncology · doi:10.1186/s13045-015-0155-z · Cited by 227 · cited 1×
“Eighteen studies were excluded after the full-text review as per our inclusion/exclusion criteria: 11 studies did not report an optimal distinction between cytoplasmic and membrane HER2/HER3 staining [29–39]; one study employed a method other than IHC and/or ISH for evaluating HER2/HER3 expression with no IHC/ISH data…”
Endo, K., Yoon, B.-I., Pairojkul, C., Demetris, A. J., & Sirica, A. E. (2002) · Hepatology · doi:10.1053/jhep.2002.34435 · Cited by 188
Resiliency and Vulnerability in the HER2-HER3 Tumorigenic Driver
Amin, D. N., Sergina, N., Ahuja, D., McMahon, M., Blair, J. A., Wang, D., Hann, B., Koch, K. M., Shokat, K. M., & Moasser, M. M. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3000389 · Cited by 175 · cited 1×
“Although all four HER family receptors are capable of dimerizing with each other, HER2 is the preferred dimerization partner [19] and the HER2–HER3 dimer seems to be the most potent HER family dimer [22, 23].”
Pignochino, Y., Sarotto, I., Peraldo-Neia, C., Penachioni, J. Y., Cavalloni, G., Migliardi, G., Casorzo, L., Chiorino, G., Risio, M., Bardelli, A., et al. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-631 · Cited by 173 · cited 4×
“2%) [73, 82], while MET expression measured by IHC ranges from 5.”
InfluentialSIERKE, S. L., CHENG, K., KIM, H.-H., & KOLAND, J. G. (1997) · Biochemical Journal · doi:10.1042/bj3220757 · Cited by 168 · cited 1×
“In contrast to HER2, HER3 can bind multiple ligands (neuregulins) [20] but it lacks a functioning kinase domain [21] and is, therefore, unable to homodimerize and to induce downstream signaling pathway activation on its own.”
Chen, J. S., Hsu, C., Chiang, N., Tsai, C. S., Tsou, H., Huang, S.-F., Bai, L., Chang, I. ‐., Shiah, H.-S., Ho, C., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv035 · Cited by 161
Leone, F., Marino, D., Cereda, S., Filippi, R., Belli, C., Spadi, R., Nasti, G., Montano, M., Amatu, A., Aprile, G., et al. (2015) · Cancer · doi:10.1002/cncr.29778 · Cited by 142
EGFR and HER2 expression in advanced biliary tract cancer
Harder, J., Waiz, O., Otto, F., Geißler, M., Olschewski, M., Weinhold, B., Blum, H. E., Schmitt-Graeff, A. H., & Opitz, O. G. (2009) · World Journal of Gastroenterology · doi:10.3748/wjg.15.4511 · Cited by 136
Aishima, S., Taguchi, K., Sugimachi, K., Shimada, M., Sugimachi, K., & Tsuneyoshi, M. (2002) · Histopathology · doi:10.1046/j.1365-2559.2002.00353.x · Cited by 119
Schlitter, A. M., Jang, K., Klöppel, G., Saka, B., Hong, S., Choi, H., Offerhaus, G. J. A., Hruban, R. H., Zen, Y., Konukiewitz, B., et al. (2015) · Modern Pathology · doi:10.1038/modpathol.2015.61 · Cited by 107
Roa, I., de Toro, G., Schalper, K. A., de Aretxabala, X., Churi, C. R., & Javle, M. M. (2014) · Europe PMC (PubMed Central) · Cited by 103
p53 and c‐erbB‐2 protein expression in adenocarcinomas and epithelial dysplasias of the gall bladder
Kamel, D., Pääkkö, P. K., Nuorva, K., Vähäkangas, K., & Soini, Y. (1993) · The Journal of Pathology · doi:10.1002/path.1711700111 · Cited by 94
Oncogene expression in cholangiocarcinoma and in normal hepatic development
Voravud, N., Foster, C. S., Gilbertson, J. A., Sikora, K., & Waxman, J. H. (1989) · Human Pathology · doi:10.1016/s0046-8177(89)80006-1 · Cited by 84
Expression and Clinical Significance of the erbB Family in Intrahepatic Cholangiocellular Carcinoma
Ito, Y., Ito, Y., Takeda, T., Sasaki, Y., Sakon, M., Yamada, T., Ishiguro, S., Imaoka, S., Tsujimoto, M., Higashiyama, S., et al. (2001) · Pathology - Research and Practice · doi:10.1078/0344-0338-00016 · Cited by 80
Settakorn, J., Kaewpila, N., Burns, G. F., & Leong, A. (2005) · Journal of Clinical Pathology · doi:10.1136/jcp.2005.026575 · Cited by 80
Shafizadeh, N., Grenert, J. P., Sahai, V., & Kakar, S. (2009) · Human Pathology · doi:10.1016/j.humpath.2009.10.002 · Cited by 77
Characterization of EGFR family gene aberrations in cholangiocarcinoma
Yang, X., Wang, W., Wang, C., Wang, L., Yang, M., Qi, M., Su, H., Sun, X., Liu, Z., Zhang, J., et al. (2014) · Oncology Reports · doi:10.3892/or.2014.3261 · Cited by 65 · cited 4×
“4 % of EHCCs, respectively, demonstrating to be a significant poor prognostic factor in EGFR-negative IHCC cases [81].”
InfluentialChoi, B., Fan, X., Deng, H., Zhang, N., & An, Z. (2012) · Cancer Medicine · doi:10.1002/cam4.10 · Cited by 57 · cited 1×
“Finally, HER3 has the ability to dimerize with both HER family members and nonHER family members such as mesenchymal epithelial transition (MET) receptor [24, 25], contributing to anti-HER2 therapy resistance.”
Law, L. Y. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.3061 · Cited by 57
Expression of HER2 and bradykinin B1receptors in precursor lesions of gallbladder carcinoma
Toledo, C., Matus, C. E., Barraza, X., Arroyo, P., Ehrenfeld, P., Figueroa, C. D., Bhoola, K. D., Pozo, M. D., & Poblete, M. T. (2012) · World Journal of Gastroenterology · doi:10.3748/wjg.v18.i11.1208 · Cited by 45
A significant subgroup of resectable gallbladder cancer patients has an HER2 positive status
Yoshida, H., Shimada, K., Kosuge, T., & Hiraoka, N. (2016) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-015-1898-1 · Cited by 44 · cited 3×
“HER3 is often correlated with poorly differentiated biliary tumors [81] and appears to be a poor prognostic factor in EHCCs [76], whereas the prognostic meaning of HER2 has not been completely clarified [79, 87].”
Kawamoto, T., Ishige, K., Thomas, M. B., Yamashita‐Kashima, Y., Shu, S., Ishikura, N., Ariizumi, S., Yamamoto, M., Kurosaki, K., & Shoda, J. (2014) · Journal of Gastroenterology · doi:10.1007/s00535-014-0984-5 · Cited by 43 · cited 5×
“Ten studies [55, 56, 59, 63, 64, 77, 80, 82, 83, 85] and five studies [59, 68, 72, 73, 78] had data for both HER2 expression and amplification in the Bunselected^ and Bselected^ population, respectively.”
InfluentialExpression of p21(Wafl/Cip1), p57(Kip2) and HER2/neu in patients with gallbladder cancer.
Puhalla, H., Wrba, F., Kandioler, D., Lehnert, M., Huynh, A. T., Gruenberger, T., Tamandl, D., & Filipits, M. (2007) · PubMed · Cited by 38
Subbiah, I. M., Subbiah, V., Tsimberidou, A. M., Naing, A., Kaseb, A. O., Javle, M. M., Fu, S., Hong, D. S., Piha-Paul, S. A., Wheler, J. J., et al. (2013) · Oncotarget · doi:10.18632/oncotarget.832 · Cited by 36
Gene amplification of Myc and its coamplification with ERBB2 and EGFR in gallbladder adenocarcinoma.
Ooi, A., Suzuki, S., Nakazawa, K., Itakura, J., Imoto, I., Nakamura, H., & Dobashi, Y. (2009) · PubMed · Cited by 36
Targeted Therapy in Biliary Tract Cancers
Merla, A., Liu, K. G., & Rajdev, L. N. (2015) · Current Treatment Options in Oncology · doi:10.1007/s11864-015-0366-0 · Cited by 33
SOX4 is associated with poor prognosis in cholangiocarcinoma
Wang, W., Zhang, J., Zhan, X., Lin, T., Yang, M., Hu, J., Han, B., & Hu, S. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.08.124 · Cited by 32 · cited 1×
“Ten studies [55, 56, 59, 63, 64, 77, 80, 82, 83, 85] and five studies [59, 68, 72, 73, 78] had data for both HER2 expression and amplification in the Bunselected^ and Bselected^ population, respectively.”
HER3 overexpression is a prognostic indicator of extrahepatic cholangiocarcinoma
Lee, H. J., Chung, J., Hewitt, S. M., Yu, E., & Hong, S. (2012) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-012-1321-0 · Cited by 31 · cited 7×
“According to the primary tumor site, the number of studies and number of patients reported were as follows: CC (24 studies; 2102 patients; 55 % of all patients reported), IHCCs (13 studies; 924 patients; 24% of all patients reported; 44% of all CC patients), EHCCs (12 studies; 920 patients; 24 % of all patients report…”
InfluentialSuder, A., Ang, J. E., Kyle, F. J., Harris, D., Rudman, S. M., Kristeleit, R. S., Solca, F., Uttenreuther‐Fischer, M., Pemberton, K., Pelling, K., et al. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.07.041 · Cited by 30 · cited 1×
“Eighteen studies were excluded after the full-text review as per our inclusion/exclusion criteria: 11 studies did not report an optimal distinction between cytoplasmic and membrane HER2/HER3 staining [29–39]; one study employed a method other than IHC and/or ISH for evaluating HER2/HER3 expression with no IHC/ISH data…”
Kalekou, H., & Miliaras, D. (2004) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2004.03357.x · Cited by 30
Immunophenotyping and oncogene amplifications in tumors of the papilla of Vater
Baumhoer, D., Zlobec, I., Tornillo, L., Dietmaier, W., Wuensch, P. H., Hartmann, A., Sessa, F., Ruemmele, P., & Terracciano, L. (2008) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-008-0669-7 · Cited by 16 · cited 1×
“Thirty-eight studies reported HER2 positivity assessed by IHC (Table 3); two studies did not perform HER2 IHC analysis [66, 85].”
Cited by
New Horizons for Precision Medicine in Biliary Tract Cancers
Valle, J. W., Lamarca, A., Goyal, L., Barriuso, J., & Zhu, A. X. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0245 · Cited by 626
Self-citationMolecular targeted therapies: Ready for “prime time” in biliary tract cancer
Lamarca, A., Barriuso, J., McNamara, M. G., & Valle, J. W. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.03.007 · Cited by 367
Self-citationHarding, J. J., Fan, J., Oh, D.-Y., Choi, H. J., Kim, J. W., Chang, H.-M., Bao, L., Sun, H.-C., Macarulla, T., Xie, F., et al. (2023) · The Lancet Oncology · doi:10.1016/s1470-2045(23)00242-5 · Cited by 291
Targeting CLDN18.2 in cancers of the gastrointestinal tract: new drugs and new indications
Chen, J., Xu, Z., Hu, C., Zhang, S., Zi, M., Yuan, L., & Cheng, X. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1132319 · Cited by 78
Metadata
- Authors
- Galdy, S., Lamarca, A., McNamara, M. G., Hubner, R. A., Cella, C. A., Fazio, N., & Valle, J. W.
- Venue
- Cancer and Metastasis Reviews
- Published
- 2016-12-15
- Volume
- 36
- Issue
- 1
- Pages
- 141-157
- ISSN
- 0167-7659 (ISSN-L)
- 1573-7233
- OpenAlex
- W2567683174
- Cited by
- 209
- References
- 65
- FWCI
- 2.20
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.